Literature DB >> 17910895

Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.

Ian S Zagon1, Kristen A Rahn, Patricia J McLaughlin.   

Abstract

This study was designed to examine the role of opioids on cell migration, chemotaxis, invasion, and adhesion, with an emphasis on whether the opioid growth factor (OGF, [Met(5)]-enkephalin) or the opioid antagonist naltrexone (NTX) impacts any or all of these processes. Drug concentrations of OGF and NTX known to depress or stimulate, respectively, cell proliferation and growth were analyzed. Three different human cancers (pancreatic, colon, and squamous cell carcinoma of the head and neck), represented by seven different cancer cell lines (PANC-1, MIA PaCa-2, BxPC-3, CAL-27, SCC-1, HCT-116, and HT-29), were evaluated. In addition, the influence of a variety of other natural and synthetic opioids on cell motility, invasion, and adhesion was assessed. Positive and negative controls were included for comparison. OGF and NTX at concentrations of 10(-4) to 10(-6)M, and dynorphin A1-8, beta-endorphin, endomorphin-1, endomorphin-2, leucine enkephalin, [D-Pen(2,5)]-enkephalin (DPDPE), [D-Ala(2), MePhe(4), Glycol(5)]-enkephalin (DAMGO), morphine, and U69,593 at concentrations of 10(-6)M, did not alter cell migration, chemotaxis, or invasion of any cancer cell line. OGF and NTX at a concentration of 10(-6)M, and incubation for 24 or 72h, did not change adhesion of these cancer cells to collagen I, collagen IV, fibronectin, laminin, or vitronectin. Moreover, all other opioids tested at 10(-6)M concentrations and for 24h had no effect on adhesion. These results indicate that the inhibitory or stimulatory actions of OGF and NTX, respectively, on cell replication and growth are independent of cell migration, chemotaxis, invasion, and adhesive properties. Moreover, a variety of other exogenous and endogenous opioids, many specific for the micro, delta, or kappa opioid receptors, also did not alter these biological processes, consonant with previous observations of a lack of effects of these compounds and their receptors on the biology of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17910895     DOI: 10.1016/j.npep.2007.08.002

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  6 in total

Review 1.  Opioid growth factor and the treatment of human pancreatic cancer: a review.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?

Authors:  Hidetomo Niwa; David J Rowbotham; David G Lambert; Donal J Buggy
Journal:  J Anesth       Date:  2013-05-14       Impact factor: 2.078

3.  The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.

Authors:  Fan Cheng; Patricia J McLaughlin; Michael F Verderame; Ian S Zagon
Journal:  Mol Biol Cell       Date:  2008-10-15       Impact factor: 4.138

Review 4.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

5.  The expression of kappa-opioid receptor promotes the migration of breast cancer cells in vitro.

Authors:  Huiqing Li; Zhenzhen Ma; Yunlong Lei
Journal:  BMC Anesthesiol       Date:  2021-08-30       Impact factor: 2.217

6.  Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.

Authors:  Inka Regine Weingaertner; Sarah Koutnik; Hermann Ammer
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.